<?xml version="1.0" encoding="UTF-8"?>
<drugbank xmlns="http://www.drugbank.ca" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.drugbank.ca http://www.drugbank.ca/docs/drugbank.xsd" version="5.1" exported-on="2018-07-03">
<drug type="biotech" created="2005-06-13" updated="2018-07-02">
  <drugbank-id primary="true">DB00001</drugbank-id>
  <drugbank-id>BTD00024</drugbank-id>
  <drugbank-id>BIOD00024</drugbank-id>
  <name>Lepirudin</name>
  <description>Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.</description>
  <cas-number>138068-37-8</cas-number>
  <unii>Y43GF64R34</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>16244762</pubmed-id>
        <citation>Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4.</citation>
      </article>
      <article>
        <pubmed-id>16690967</pubmed-id>
        <citation>Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11.</citation>
      </article>
      <article>
        <pubmed-id>16241940</pubmed-id>
        <citation>Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>Google books</title>
        <url>http://books.google.com/books?id=iadLoXoQkWEC&amp;pg=PA440</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of heparin-induced thrombocytopenia</indication>
  <pharmacodynamics>Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.</pharmacodynamics>
  <mechanism-of-action>Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade. </mechanism-of-action>
  <toxicity>In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.</toxicity>
  <metabolism>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</metabolism>
  <absorption>Bioavailability is 100% following injection.</absorption>
  <half-life>Approximately 1.3 hours</half-life>
  <protein-binding/>
  <route-of-elimination>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</route-of-elimination>
  <volume-of-distribution>* 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]&#13;
* 18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]&#13;
* 18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]&#13;
* 32.1 L [HIT patients (n = 73)]</volume-of-distribution>
  <clearance>* 164 ml/min [Healthy 18-60 yrs]&#13;
* 139 ml/min [Healthy 65-80 yrs]&#13;
* 61 ml/min [renal impaired]&#13;
* 114 ml/min [HIT (Heparin-induced thrombocytopenia)]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Hirudin variant-1</synonym>
    <synonym language="" coder="">Lepirudin recombinant</synonym>
  </synonyms>
  <products>
    <product>
      <name>Refludan</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240996</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-01-31</started-marketing-on>
      <ended-marketing-on>2013-07-26</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Refludan</name>
      <labeller>Celgene Europe Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000122</ema-product-code>
      <ema-ma-number>EU/1/97/035/001</ema-ma-number>
      <started-marketing-on>1997-03-13</started-marketing-on>
      <ended-marketing-on>2012-07-27</ended-marketing-on>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Refludan</name>
      <labeller>Celgene Europe Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000122</ema-product-code>
      <ema-ma-number>EU/1/97/035/002</ema-ma-number>
      <started-marketing-on>1997-03-13</started-marketing-on>
      <ended-marketing-on>2012-07-27</ended-marketing-on>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Refludan</name>
      <labeller>Celgene Europe Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000122</ema-product-code>
      <ema-ma-number>EU/1/97/035/003</ema-ma-number>
      <started-marketing-on>1997-03-13</started-marketing-on>
      <ended-marketing-on>2012-07-27</ended-marketing-on>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>20 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Refludan</name>
      <labeller>Celgene Europe Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000122</ema-product-code>
      <ema-ma-number>EU/1/97/035/004</ema-ma-number>
      <started-marketing-on>1997-03-13</started-marketing-on>
      <ended-marketing-on>2012-07-27</ended-marketing-on>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>20 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Bayer Healthcare</name>
      <url>http://www.bayerhealthcare.com</url>
    </packager>
    <packager>
      <name>Berlex Labs</name>
      <url>http://www.berlex.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Bayer healthcare pharmaceuticals inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Refludan 50 mg vial</description>
      <cost currency="USD">273.19</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anticoagulants</category>
      <mesh-id>D000925</mesh-id>
    </category>
    <category>
      <category>Antithrombin Proteins</category>
      <mesh-id>D058833</mesh-id>
    </category>
    <category>
      <category>Antithrombins</category>
      <mesh-id>D000991</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Fibrin Modulating Agents</category>
      <mesh-id>D050299</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Protease Inhibitors</category>
      <mesh-id>D011480</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Proteinase Inhibitors</category>
      <mesh-id>D015842</mesh-id>
    </category>
    <category>
      <category>Serpins</category>
      <mesh-id>D015843</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>20 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B01AE02">
      <level code="B01AE">Direct thrombin inhibitors</level>
      <level code="B01A">ANTITHROMBOTIC AGENTS</level>
      <level code="B01">ANTITHROMBOTIC AGENTS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00001.pdf?1265924858</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00001.pdf?1368416245</msds>
  <patents>
    <patent>
      <number>5180668</number>
      <country>United States</country>
      <approved>1993-01-19</approved>
      <expires>2010-01-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of Lepirudin can be increased when combined with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The serum concentration of Alfuzosin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Apixaban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Edoxaban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Lepirudin may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The serum concentration of Lovastatin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>Urokinase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of adverse effects can be increased when Vorapaxar is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The serum concentration of Midazolam can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The serum concentration of Lepirudin can be decreased when it is combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Cabergoline can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Bromocriptine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The serum concentration of Dihydroergotamine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The serum concentration of Ergotamine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The serum concentration of Ergoloid mesylate can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergonovine</name>
      <description>The serum concentration of Ergonovine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00353</drugbank-id>
      <name>Methylergometrine</name>
      <description>The serum concentration of Methylergometrine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The serum concentration of Triazolam can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03404</drugbank-id>
      <name>Hemin</name>
      <description>Hemin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinyl Estradiol</name>
      <description>The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The serum concentration of Mestranol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10532</drugbank-id>
      <name>Garlic</name>
      <description>The serum concentration of Lepirudin can be decreased when it is combined with Garlic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The metabolism of Tacrolimus can be decreased when combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Pethidine</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Pethidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The serum concentration of Alprazolam can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Lepirudin can be decreased when it is combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The metabolism of Lepirudin can be increased when combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The serum concentration of Delavirdine can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>Chlorotrianisene may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Conjugated estrogens may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>Estrone may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00890</drugbank-id>
      <name>Dienestrol</name>
      <description>Dienestrol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>Genistein may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>Hexestrol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>Equol</name>
      <description>Equol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12179</drugbank-id>
      <name>Secoisolariciresinol</name>
      <description>Secoisolariciresinol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13182</drugbank-id>
      <name>Daidzein</name>
      <description>Daidzein may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13386</drugbank-id>
      <name>Epimestrol</name>
      <description>Epimestrol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>Estriol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>Methallenestril may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13418</drugbank-id>
      <name>Moxestrol</name>
      <description>Moxestrol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Estradiol acetate may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Estrogens, esterified</name>
      <description>Estrogens, esterified may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06401</drugbank-id>
      <name>Bazedoxifene</name>
      <description>Bazedoxifene may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04865</drugbank-id>
      <name>Omacetaxine mepesuccinate</name>
      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Nefazodone can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Allylestrenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etonogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroxyprogesterone caproate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Desogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00378</drugbank-id>
      <name>Dydrogesterone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Dydrogesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestodene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11372</drugbank-id>
      <name>Altrenogest</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Altrenogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestrinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09124</drugbank-id>
      <name>Medrogestone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medrogestone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11636</drugbank-id>
      <name>Nomegestrol</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Nomegestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13230</drugbank-id>
      <name>Gestonorone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestonorone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13533</drugbank-id>
      <name>Methylestrenolone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Methylestrenolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13563</drugbank-id>
      <name>Norgestrienone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Norgestrienone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13602</drugbank-id>
      <name>Promegestone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Promegestone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13857</drugbank-id>
      <name>Demegestone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Demegestone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Levonorgestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Dienogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Lynestrenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13528</drugbank-id>
      <name>Chlormadinone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Chlormadinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13685</drugbank-id>
      <name>Quingestanol</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Quingestanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13866</drugbank-id>
      <name>Ethynodiol</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ethynodiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone undecanoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The serum concentration of Riociguat can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The serum concentration of Sildenafil can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Diltiazem can be decreased when combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be decreased when combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Pentosan Polysulfate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09568</drugbank-id>
      <name>Omega-3-carboxylic acids</name>
      <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Omega-3-carboxylic acids.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The serum concentration of Protriptyline can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The serum concentration of Nortriptyline can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The serum concentration of Doxepin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The serum concentration of Desipramine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The serum concentration of Clomipramine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The serum concentration of Butriptyline can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>The serum concentration of Amitriptylinoxide can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The serum concentration of Melitracen can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>The serum concentration of Dimetacrine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The serum concentration of Amineptine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The serum concentration of Dosulepin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The serum concentration of Tianeptine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The serum concentration of Opipramol can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>The serum concentration of Dibenzepin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The serum concentration of Lofepramine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>The serum concentration of Iprindole can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The serum concentration of Amoxapine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>The serum concentration of Abacavir can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00109</drugbank-id>
      <name>Enfuvirtide</name>
      <description>The serum concentration of Enfuvirtide can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The serum concentration of Etravirine can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>Dasatinib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Deoxycholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibrutinib is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00048</drugbank-id>
      <name>Collagenase clostridium histolyticum</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06206</drugbank-id>
      <name>Sugammadex</name>
      <description>Sugammadex may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>Ketorolac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>Diclofenac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>Flurbiprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00963</drugbank-id>
      <name>Bromfenac</name>
      <description>Bromfenac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06802</drugbank-id>
      <name>Nepafenac</name>
      <description>Nepafenac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>Etanercept may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00179</drugbank-id>
      <name>Masoprocol</name>
      <description>Masoprocol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00210</drugbank-id>
      <name>Adapalene</name>
      <description>Adapalene may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>Indomethacin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>Pimecrolimus may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>Nabumetone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>Tenoxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>Celecoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>Tolmetin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>Rofecoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>Piroxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>Fenoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>Valdecoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>Sulindac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Chloroquine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Mycophenolate mofetil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00735</drugbank-id>
      <name>Naftifine</name>
      <description>Naftifine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>Zileuton may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>Etodolac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>Olopatadine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>Mefenamic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Naproxen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Sulfasalazine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>Phenylbutazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>Meloxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00870</drugbank-id>
      <name>Suprofen</name>
      <description>Suprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>Meclofenamic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>Oxaprozin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Ketoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Mycophenolic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>Ibuprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>Leflunomide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>Lumiracoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Magnesium salicylate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>Salsalate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>Choline magnesium trisalicylate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>Antipyrine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Tiaprofenic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>Etoricoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>Castanospermine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>Oxyphenbutazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic Acid</name>
      <description>Niflumic Acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>Benoxaprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>Metamizole may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>Zomepirac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>Pirfenidone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>SRT501 may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05173</drugbank-id>
      <name>PTC299</name>
      <description>PTC299 may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05289</drugbank-id>
      <name>Tarenflurbil</name>
      <description>Tarenflurbil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>Apremilast may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>Andrographolide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Icatibant may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06246</drugbank-id>
      <name>Exisulind</name>
      <description>Exisulind may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>Lornoxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Aceclofenac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>Zaltoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>Seratrodast may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>Azapropazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>Felbinac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>Ferulic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>Parecoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>Salicylamide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>Teriflunomide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08921</drugbank-id>
      <name>(4R)-limonene</name>
      <description>(4R)-limonene may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>Kebuzone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>Isoxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>Indoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>Ibuproxam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>Floctafenine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>Fenbufen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>Etofenamate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>Epirizole may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>Loxoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>Droxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic Acid</name>
      <description>Tolfenamic Acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>Clonixin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Propacetamol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Evening primrose oil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11444</drugbank-id>
      <name>Orgotein</name>
      <description>Orgotein may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>Tepoxalin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>Flunixin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>Curcumin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11687</drugbank-id>
      <name>E-6201</name>
      <description>E-6201 may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>Anisodamine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>Duvelisib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>Triptolide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12094</drugbank-id>
      <name>Semapimod</name>
      <description>Semapimod may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12160</drugbank-id>
      <name>Bucillamine</name>
      <description>Bucillamine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>Lisofylline may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Nafamostat may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>Mizoribine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12618</drugbank-id>
      <name>Apocynin</name>
      <description>Apocynin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>Higenamine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>Tinoridine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13063</drugbank-id>
      <name>Parthenolide</name>
      <description>Parthenolide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13131</drugbank-id>
      <name>Serrapeptase</name>
      <description>Serrapeptase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>Alclofenac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>Fentiazac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13227</drugbank-id>
      <name>Tribenoside</name>
      <description>Tribenoside may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>Suxibuzone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>Bumadizone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>Alminoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>Flunoxaprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13346</drugbank-id>
      <name>Bufexamac</name>
      <description>Bufexamac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>Feprazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>Difenpiramide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>Nifenazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>Lonazolac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>Tenidap may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>Bendazac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>Pranoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>Propyphenazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>Proglumetacin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>Guacetisal may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>Bevonium may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>Ethenzamide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>Carbaspirin calcium may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>Mofebutazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>Proquazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>Benorilate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>Pirprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>Imidazole salicylate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>Benzydamine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14043</drugbank-id>
      <name>Palmidrol</name>
      <description>Palmidrol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11133</drugbank-id>
      <name>Omega-3 fatty acids</name>
      <description>Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00163</drugbank-id>
      <name>Vitamin E</name>
      <description>Vitamin E may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Abciximab may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Becaplermin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Dicoumarol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Argatroban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Ardeparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Phenindione may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>Fondaparinux sodium may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Warfarin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Phenprocoumon may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Edetic Acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Heparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Enoxaparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Acenocoumarol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Citric Acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Ximelagatran may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Ancrod may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06154</drugbank-id>
      <name>Pentaerythritol Tetranitrate</name>
      <description>Pentaerythritol Tetranitrate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Sulodexide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Idraparinux may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Otamixaban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Danaparoid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Dalteparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Ethyl biscoumacetate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Nadroparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Dextran may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Reviparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Certoparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Desirudin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Protocatechualdehyde may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Protein C may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Antithrombin III human may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>Letaxaban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Darexaban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Gabexate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13124</drugbank-id>
      <name>Troxerutin</name>
      <description>Troxerutin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Fluindione may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Protein S human may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>Melagatran may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium Citrate</name>
      <description>Potassium Citrate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium Citrate</name>
      <description>Sodium Citrate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>Aminosalicylic Acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>Dersalazine</name>
      <description>Dersalazine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06807</drugbank-id>
      <name>Phenyl aminosalicylate</name>
      <description>Phenyl aminosalicylate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13509</drugbank-id>
      <name>Aloxiprin</name>
      <description>Aloxiprin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13864</drugbank-id>
      <name>Hemoglobin crosfumaril</name>
      <description>Hemoglobin crosfumaril may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09543</drugbank-id>
      <name>Methyl salicylate</name>
      <description>Methyl salicylate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11079</drugbank-id>
      <name>Trolamine salicylate</name>
      <description>Trolamine salicylate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>Alteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>Reteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>Anistreplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>Tenecteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>Drotrecogin alfa may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Defibrotide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>Tinzaparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>Brinase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>Saruplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>Streptokinase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>Desmoteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>Fibrinolysin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>Caplacizumab may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06392</drugbank-id>
      <name>eplivanserine</name>
      <description>eplivanserine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>Astaxanthin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09005</drugbank-id>
      <name>Batroxobin</name>
      <description>Batroxobin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12017</drugbank-id>
      <name>Ozagrel</name>
      <description>Ozagrel may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>Sarpogrelate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12177</drugbank-id>
      <name>Eplivanserin</name>
      <description>Eplivanserin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>Treprostinil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Beraprost may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Prasugrel may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Cangrelor may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Triflusal may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>Ticagrelor may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>Ditazole may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>Bemiparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>Parnaparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>Selexipag may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Indobufen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>Clorindione may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13327</drugbank-id>
      <name>Picotamide</name>
      <description>Picotamide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>Diphenadione may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13367</drugbank-id>
      <name>Cloricromen</name>
      <description>Cloricromen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>Tioclomarol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>Epinastine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>Alprostadil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>Tesmilifene may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12321</drugbank-id>
      <name>Ifetroban</name>
      <description>Ifetroban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12771</drugbank-id>
      <name>Hydroxytyrosol</name>
      <description>Hydroxytyrosol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>Linsidomine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>Buflomedil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13929</drugbank-id>
      <name>Relcovaptan</name>
      <description>Relcovaptan may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The serum concentration of Theophylline can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The serum concentration of Dyphylline can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The serum concentration of Aminophylline can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic Acid</name>
      <description>The serum concentration of Valproic Acid can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Zidovudine can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11051</drugbank-id>
      <name>Azficel-T</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Azficel-T.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00001 sequence
LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP
EEYLQ</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>65 °C</value>
      <source>Otto, A. &amp; Seckler, R. Eur. J. Biochem. 202:67-73 (1991)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.777</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>4.04</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>6963.425</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C287H440N80O110S6</value>
      <source/>
    </property>
  </experimental-properties>
  <calculated-properties>
  <property>
      <kind>SMILES</kind>
      <value>CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C24H32N2O2/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22/h4-13,20,23H,3,14-19H2,1-2H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>BSHWLCACYCVCJE-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11916</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507011</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D06880</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450195</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01050</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000541</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Lepirudin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201666</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/lepirudin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/lepirudin.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP00278</smpdb-id>
      <name>Lepirudin Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00001</drugbank-id>
          <name>Lepirudin</name>
        </drug>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000048</id>
      <name>Prothrombin</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10505536</pubmed-id>
            <citation>Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M.</citation>
          </article>
          <article>
            <pubmed-id>10912644</pubmed-id>
            <citation>Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51.</citation>
          </article>
          <article>
            <pubmed-id>11055889</pubmed-id>
            <citation>Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9.</citation>
          </article>
          <article>
            <pubmed-id>11467439</pubmed-id>
            <citation>Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25.</citation>
          </article>
          <article>
            <pubmed-id>11807012</pubmed-id>
            <citation>Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00734" source="Swiss-Prot">
    <name>Prothrombin</name>
    <general-function>Thrombospondin receptor activity</general-function>
    <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.</specific-function>
    <gene-name>F2</gene-name>
    <locus>11p11-q12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>5.7</theoretical-pi>
    <molecular-weight>70036.295</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3535</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>F2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M17262</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>339641</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2362</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00734</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ide</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.5</synonym>
      <synonym>Coagulation factor II</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016004|Prothrombin
MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016005|Prothrombin (F2)
ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC
GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG
ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
GGAGAGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00594</identifier>
        <name>Gla</name>
      </pfam>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF09396</identifier>
        <name>Thrombin_light</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>thrombospondin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell shape</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to inactivity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to wounding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute-phase response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, intrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of collagen biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytosolic calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to mechanical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>leukocyte migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of reactive oxygen species metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of astrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood coagulation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2018-07-03">
  <drugbank-id primary="true">DB00002</drugbank-id>
  <drugbank-id>BTD00071</drugbank-id>
  <drugbank-id>BIOD00071</drugbank-id>
  <name>Cetuximab</name>
  <description>Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company. In the United States, a regimen of cetuximab costs approximately $30,790 for an eight-week course.</description>
  <cas-number>205923-56-4</cas-number>
  <unii>PQX0D8J21J</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>10480573</pubmed-id>
        <citation>Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90.</citation>
      </article>
      <article>
        <pubmed-id>10601294</pubmed-id>
        <citation>Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91.</citation>
      </article>
      <article>
        <pubmed-id>10628369</pubmed-id>
        <citation>Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5.</citation>
      </article>
      <article>
        <pubmed-id>11408594</pubmed-id>
        <citation>Burke P, Schooler K, Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001 Jun;12(6):1897-910.</citation>
      </article>
      <article>
        <pubmed-id>11431346</pubmed-id>
        <citation>Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001 Jul 1;61(13):5090-101.</citation>
      </article>
      <article>
        <pubmed-id>11752352</pubmed-id>
        <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
      </article>
      <article>
        <pubmed-id>15269308</pubmed-id>
        <citation>Schrag D: The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med. 2004 Jul 22;351(4):317-9.</citation>
      </article>
      <article>
        <pubmed-id>16336752</pubmed-id>
        <citation>Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.</indication>
  <pharmacodynamics>Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor–alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.</pharmacodynamics>
  <mechanism-of-action>Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.</mechanism-of-action>
  <toxicity>Pulmonary Toxicity&#13;
&#13;
Interstitial lung disease (ILD) was reported in 3 of 633 (&lt;0.5%) patients with advanced colorectal cancer receiving cetuximab. Interstitial pneumonitis with non-cardiogenic pulmonary edema resulting in death was reported in one case. Two patients had pre-existing fibrotic lung disease and experienced an acute exacerbation of their disease while receiving cetuximab in combination with irinotecan. In the clinical investigational program, an additional case of interstitial pneumonitis was reported in a patient with head and neck cancer treated with cetuximab and cisplatin. The onset of symptoms occurred between the fourth and eleventh doses of treatment in all reported cases.</toxicity>
  <metabolism/>
  <absorption/>
  <half-life>The mean half-life for Cetuximab is 114 hours (range 75-188 hours).</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>appeared to be independent of dose and approximated the vascular space of 2-3 L/m2.</volume-of-distribution>
  <clearance>Female patients had 25% lower intrinsic clearance than male patients.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="German/Spanish" coder="INN">Cetuximab</synonym>
    <synonym language="French" coder="INN">Cétuximab</synonym>
    <synonym language="Latin" coder="INN">Cetuximabum</synonym>
    <synonym language="" coder="WHO">Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer</synonym>
  </synonyms>
  <products>
    <product>
      <name>Erbitux</name>
      <labeller>Im Clone Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02271249</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Erbitux</name>
      <labeller>Merck K Ga A</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000558</ema-product-code>
      <ema-ma-number>EU/1/04/281/003</ema-ma-number>
      <started-marketing-on>2004-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Erbitux</name>
      <labeller>Merck K Ga A</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000558</ema-product-code>
      <ema-ma-number>EU/1/04/281/005</ema-ma-number>
      <started-marketing-on>2004-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Erbitux</name>
      <labeller>Im Clone Llc</labeller>
      <ndc-id/>
      <ndc-product-code>66733-948</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125084</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Erbitux</name>
      <labeller>Im Clone Llc</labeller>
      <ndc-id/>
      <ndc-product-code>66733-958</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125084</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Catalent Pharma Solutions</name>
      <url>http://www.catalent.com</url>
    </packager>
    <packager>
      <name>ImClone Systems Inc.</name>
      <url>http://www.imclone.com</url>
    </packager>
    <packager>
      <name>Oso Biopharmaceuticals Manufacturing LLC</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Antibodies, Monoclonal</category>
      <mesh-id>D000911</mesh-id>
    </category>
    <category>
      <category>Antibodies, Monoclonal, Humanized</category>
      <mesh-id>D061067</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Epidermal Growth Factor Receptor Antagonist</category>
      <mesh-id/>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>5 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>2 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>2 mg/mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L01XC06">
      <level code="L01XC">Monoclonal antibodies</level>
      <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
      <level code="L01">ANTINEOPLASTIC AGENTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>10:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00002.pdf?1265922813</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00002.pdf?1458412933</msds>
  <patents>
    <patent>
      <number>1340417</number>
      <country>Canada</country>
      <approved>1999-03-02</approved>
      <expires>2016-03-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Cetuximab is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09103</drugbank-id>
      <name>Ancestim</name>
      <description>The risk or severity of cytotoxicity can be increased when Ancestim is combined with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/Attenuated)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10583</drugbank-id>
      <name>Clostridium tetani toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10584</drugbank-id>
      <name>Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10276</drugbank-id>
      <name>Rotavirus Vaccine</name>
      <description>The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05322</drugbank-id>
      <name>INGN 201</name>
      <description>The therapeutic efficacy of INGN 201 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12568</drugbank-id>
      <name>Tecemotide</name>
      <description>The therapeutic efficacy of Tecemotide can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid Vaccine</name>
      <description>The therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10769</drugbank-id>
      <name>Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10803</drugbank-id>
      <name>Salmonella typhi ty2 vi polysaccharide antigen</name>
      <description>The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10989</drugbank-id>
      <name>Hepatitis A Vaccine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Salmonella typhi ty21a live antigen</name>
      <description>The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11603</drugbank-id>
      <name>Human rabies virus immune globulin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11627</drugbank-id>
      <name>Hepatitis B Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Paclitaxel is combined with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Docetaxel is combined with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>Cymarin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>Proscillaridin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>Metildigoxin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>Peruvoside may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>Lanatoside C may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>Gitoformate may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>Acetyldigoxin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Oleandrin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00076</drugbank-id>
      <name>Digoxin Immune Fab (Ovine)</name>
      <description>Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Bevacizumab may increase the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Cetuximab heavy chain
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN
TPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAA
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
    <sequence format="FASTA">&gt;Cetuximab light chain
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS
RFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
      <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.413</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.48</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>145781.6</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C6484H10042N1732O2023S36</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13175</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507042</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03455</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00228</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA10040</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DNC000788</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Cetuximab</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201577</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/erbitux.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/cetuximab.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP00474</smpdb-id>
      <name>Cetuximab Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00002</drugbank-id>
          <name>Cetuximab</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00533</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects>
    <effect>
      <protein-name>Low affinity immunoglobulin gamma Fc region receptor II-a</protein-name>
      <gene-symbol>FCGR2A</gene-symbol>
      <uniprot-id>P12318</uniprot-id>
      <rs-id>rs1801274</rs-id>
      <allele/>
      <defining-change>H allelle</defining-change>
      <description>Patients with this genotype may have increased progression-free survival time when using cetuximab to treat colorectal cancer.</description>
      <pubmed-id>17704420</pubmed-id>
    </effect>
    <effect>
      <protein-name>Low affinity immunoglobulin gamma Fc region receptor III-A</protein-name>
      <gene-symbol>FCGR3A</gene-symbol>
      <uniprot-id>P08637</uniprot-id>
      <rs-id>rs396991</rs-id>
      <allele/>
      <defining-change>G &gt; T</defining-change>
      <description>Patients with this genotype have increased progression-free survival time when using cetuximab to treat colorectal cancer.</description>
      <pubmed-id>17704420</pubmed-id>
    </effect>
  </snp-effects>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000767</id>
      <name>Epidermal growth factor receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10480573</pubmed-id>
            <citation>Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90.</citation>
          </article>
          <article>
            <pubmed-id>10601294</pubmed-id>
            <citation>Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91.</citation>
          </article>
          <article>
            <pubmed-id>10628369</pubmed-id>
            <citation>Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5.</citation>
          </article>
          <article>
            <pubmed-id>11408594</pubmed-id>
            <citation>Burke P, Schooler K, Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001 Jun;12(6):1897-910.</citation>
          </article>
          <article>
            <pubmed-id>11431346</pubmed-id>
            <citation>Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001 Jul 1;61(13):5090-101.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00533" source="Swiss-Prot">
    <name>Epidermal growth factor receptor</name>
    <general-function>Ubiquitin protein ligase binding</general-function>
    <specific-function>Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.Isoform 2 may act as an antagonist of EGF action.</specific-function>
    <gene-name>EGFR</gene-name>
    <locus>7p12</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>646-668</transmembrane-regions>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>6.67</theoretical-pi>
    <molecular-weight>134276.185</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3236</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>EGFR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X00588</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>757924</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1797</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00533</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>EGFR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>2.7.10.1</synonym>
      <synonym>ERBB</synonym>
      <synonym>ERBB1</synonym>
      <synonym>HER1</synonym>
      <synonym>Proto-oncogene c-ErbB-1</synonym>
      <synonym>Receptor tyrosine-protein kinase erbB-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001530|Epidermal growth factor receptor
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
APQSSEFIGA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019007|Epidermal growth factor receptor (EGFR)
ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG
GCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG
TTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG
GTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG
ACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT
TTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA
GTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA
CAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG
AGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC
CAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG
GGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC
GGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC
ACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC
AAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC
CCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG
GTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA
GACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA
GGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA
AACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC
TTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA
ATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT
GAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC
GTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT
GTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG
TTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG
GCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC
AGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAC
CTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA
GAGTGCCTGCCTCAGGCCAx2rm:hasChild [ 
                    a x2rm:drugbank\/drug\/targets\/target\/polypeptide\/pfams ;
                    x2rm:hasChild [ 
                        a x2rm:drugbank\/drug\/targets\/target\/polypeptide\/pfams\/pfam ;
                        x2rm:hasChild [ 
                            a x2rm:drugbank\/drug\/targets\/target\/polypeptide\/pfams\/pfam/\identifier ;
                            x2rm:hasValue ?polyPfamId
                        ] ;
                        x2rm:hasChild [ 
                            a x2rm:drugbank\/drug\/targets\/target\/polypeptide\/pfams\/pfam/\name ;
                            x2rm:hasValue ?polyPfamName
                        ]
                    ]
                ]TGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG
GGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC
CATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG
CCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG
GCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG
AGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC
CAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC
GGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT
CCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC
GATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC
TGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC
TATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG
ATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC
AGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA
CTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG
ATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC
GGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC
AGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC
ATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG
TTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC
ATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC
CTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG
CAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA
ACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC
AAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC
AGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG
CCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC
AGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC
ACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA
GGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA
GCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC
GCGCCACAAAGCAGTGAATTTATTGGAGCATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF00757</identifier>
        <name>Furin-like</name>
      </pfam>
      <pfam>
        <identifier>PF01030</identifier>
        <name>Recep_L_domain</name>
      </pfam>
      <pfam>
        <identifier>PF14843</identifier>
        <name>GF_recep_IV</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basolateral plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>early endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane raft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>multivesicular body, internal vesicle lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Shc-EGFR complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epidermal growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>actin filament binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane receptor protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor signaling protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein phosphatase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>double-stranded DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin protein ligase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>chromatin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>MAP kinase kinase kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibroblast proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epithelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase A2 activity by calcium-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to estradiol stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>morphogenesis of an epithelial fold</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to UV-A</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric oxide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of catenin import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic placenta development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>salivary gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ossification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>single organismal cell-cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein insertion into membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to amino acid stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cerebral cortex cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>digestive tract morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to epidermal growth factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of nitric-oxide synthase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA repair</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hair follicle development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning or memory</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000901</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>16336752</pubmed-id>
            <citation>Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O75015" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.</specific-function>
    <gene-name>FCGR3B</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>6.71</theoretical-pi>
    <molecular-weight>26215.64</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3620</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR3B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X16863</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31322</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>O75015</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG3B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD16B</synonym>
      <synonym>Fc-gamma RIII</synonym>
      <synonym>Fc-gamma RIII-beta</synonym>
      <synonym>Fc-gamma RIIIb</synonym>
      <synonym>FCG3</synonym>
      <synonym>FCGR3</synonym>
      <synonym>FcR-10</synonym>
      <synonym>FcRIII</synonym>
      <synonym>FcRIIIb</synonym>
      <synonym>IGFR3</synonym>
      <synonym>IgG Fc receptor III-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)
ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
TTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of defense response to virus by host</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenophagy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mitophagy in response to mitochondrial depolarization</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0002093</id>
      <name>Complement C1r subcomponent</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P00736" source="Swiss-Prot">
    <name>Complement C1r subcomponent</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system.</specific-function>
    <gene-name>C1R</gene-name>
    <locus>12p13</locus>
    <cellular-location>Cytoplasmic</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>6.24</theoretical-pi>
    <molecular-weight>80118.04</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1246</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1R</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04701</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>29539</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2334</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00736</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.41</synonym>
      <synonym>Complement component 1 subcomponent r</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011518|Complement C1r subcomponent
MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF
QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF
SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY
ELQEDTHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF
DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL
RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD
DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR
ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF
TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV
SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME
EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV
RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011519|Complement C1r subcomponent (C1R)
ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC
ATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC
AACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC
CAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT
GATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG
GGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC
TCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT
GTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG
TGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT
GAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG
GCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC
AACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT
GATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC
GGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC
AATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG
CGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC
ATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA
GGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT
GATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA
AACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC
CGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG
GAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG
GGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG
AGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC
ACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT
GCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC
CTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC
AGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG
CTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC
AACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG
GAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT
GAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT
GGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA
AGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC
AGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG
ATGGAGGAGGAGGACTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00084</identifier>
        <name>Sushi</name>
      </pfam>
      <pfam>
        <identifier>PF00431</identifier>
        <name>CUB</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0002094</id>
      <name>Complement C1q subcomponent subunit A</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02745" source="Swiss-Prot">
    <name>Complement C1q subcomponent subunit A</name>
    <general-function/>
    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.</specific-function>
    <gene-name>C1QA</gene-name>
    <locus>1p36.12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>9.45</theoretical-pi>
    <molecular-weight>26016.47</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1241</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1QA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF135157</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>4894854</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02745</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1QA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Complement C1q subcomponent subunit A precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016678|Complement C1q subcomponent subunit A
MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR
TGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI
RRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR
GQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL
IFPSA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)
ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG
GTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC
AGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG
ACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC
AAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA
GGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT
CGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG
GAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC
TTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG
GGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG
GTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC
CCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC
ATCTTCCCATCTGCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01391</identifier>
        <name>Collagen</name>
      </pfam>
      <pfam>
        <identifier>PF00386</identifier>
        <name>C1q</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>collagen trimer</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>complement component C1 complex</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0002095</id>
      <name>Complement C1q subcomponent subunit B</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02746" source="Swiss-Prot">
    <name>Complement C1q subcomponent subunit B</name>
    <general-function/>
    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.</specific-function>
    <gene-name>C1QB</gene-name>
    <locus>1p36.12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>8.87</theoretical-pi>
    <molecular-weight>26721.62</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1242</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1QB</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X03084</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>573114</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02746</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1QB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Complement C1q subcomponent subunit B precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016676|Complement C1q subcomponent subunit B
MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG
EKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ
KIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL
CVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS
IFSGFLLFPDMEA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)
ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC
CTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC
CCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA
GAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA
GGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC
CCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG
AAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC
CGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC
ACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG
TGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT
GCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG
AACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC
ATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01391</identifier>
        <name>Collagen</name>
      </pfam>
      <pfam>
        <identifier>PF00386</identifier>
        <name>C1q</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>collagen trimer</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>complement component C1 complex</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inner ear development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0002096</id>
      <name>Complement C1q subcomponent subunit C</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02747" source="Swiss-Prot">
    <name>Complement C1q subcomponent subunit C</name>
    <general-function/>
    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.</specific-function>
    <gene-name>C1QC</gene-name>
    <locus>1p36.11</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-28</signal-regions>
    <theoretical-pi>8.58</theoretical-pi>
    <molecular-weight>25773.56</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1245</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1QC</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF087892</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>33150626</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02747</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1QC_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>C1QG</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011520|Complement C1q subcomponent subunit C
MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP
GIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS
VFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV
LLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF
LLFPD</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)
ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG
CTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC
CTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA
GGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA
CCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC
CCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA
GTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC
AACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC
AAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG
CTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT
CAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT
GTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC
CTGCTCTTCCCCGACTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01391</identifier>
        <name>Collagen</name>
      </pfam>
      <pfam>
        <identifier>PF00386</identifier>
        <name>C1q</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>collagen trimer</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of granulocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of macrophage differentiation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0002097</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>17704420</pubmed-id>
            <citation>Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08637" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.</specific-function>
    <gene-name>FCGR3A</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>209-229</transmembrane-regions>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>8.21</theoretical-pi>
    <molecular-weight>29088.895</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3619</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR3A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X52645</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31324</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08637</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG3A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD16A</synonym>
      <synonym>CD16a antigen</synonym>
      <synonym>Fc-gamma RIII</synonym>
      <synonym>Fc-gamma RIII-alpha</synonym>
      <synonym>Fc-gamma RIIIa</synonym>
      <synonym>FCG3</synonym>
      <synonym>FCGR3</synonym>
      <synonym>FcR-10</synonym>
      <synonym>FcRIII</synonym>
      <synonym>FcRIIIa</synonym>
      <synonym>IGFR3</synonym>
      <synonym>IgG Fc receptor III-2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
KDHKFKWRKDPQDK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)
ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT
TTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG
CTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA
AAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT
CTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG
AGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT
GGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC
CATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT
CACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT
GGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC
AAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG
ACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA
CCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA
CTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA
TTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0001529</id>
      <name>Complement C1s subcomponent</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P09871" source="Swiss-Prot">
    <name>Complement C1s subcomponent</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.</specific-function>
    <gene-name>C1S</gene-name>
    <locus>12p13</locus>
    <cellular-location>Cytoplasmic</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-15</signal-regions>
    <theoretical-pi>4.59</theoretical-pi>
    <molecular-weight>76683.905</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1247</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1S</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X06596</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>763110</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2335</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P09871</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1S_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.42</synonym>
      <synonym>C1 esterase</synonym>
      <synonym>Complement component 1 subcomponent s</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011082|Complement C1s subcomponent
MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE
LSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF
TGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF
TALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF
VAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP
NSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG
IPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK
CVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN
REPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK
MGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV
EKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG
TYGLYTRVKNYVDWIMKTMQENSTPRED</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011083|Complement C1s subcomponent (C1S)
ATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT
GGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG
GACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG
CTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG
AGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA
GTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT
ACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT
GTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG
GAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC
ACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA
AGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA
GAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT
GTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT
ATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA
AAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC
AATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC
TGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT
TGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC
ATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT
GTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG
TATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA
TGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA
GGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT
GGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC
AGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC
AAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA
GAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA
ATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG
GATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT
CGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG
GAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA
GGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT
CCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG
ACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG
GAAAATAGCACCCCCCGTGAGGACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00084</identifier>
        <name>Sushi</name>
      </pfam>
      <pfam>
        <identifier>PF00431</identifier>
        <name>CUB</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="9">
      <id>BE0000710</id>
      <name>High affinity immunoglobulin gamma Fc receptor I</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>7547242</pubmed-id>
            <citation>Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P12314" source="Swiss-Prot">
    <name>High affinity immunoglobulin gamma Fc receptor I</name>
    <general-function>Receptor signaling protein activity</general-function>
    <specific-function>High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.</specific-function>
    <gene-name>FCGR1A</gene-name>
    <locus>1q21.2-q21.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>293-313</transmembrane-regions>
    <signal-regions>1-15</signal-regions>
    <theoretical-pi>8.08</theoretical-pi>
    <molecular-weight>42631.525</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3613</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X14356</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31332</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P12314</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCGR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fc-gamma RI</synonym>
      <synonym>Fc-gamma RIA</synonym>
      <synonym>FCG1</synonym>
      <synonym>FcgammaRIa</synonym>
      <synonym>FCGR1</synonym>
      <synonym>FcRI</synonym>
      <synonym>IGFR1</synonym>
      <synonym>IgG Fc receptor I</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I
MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
LQEGVHRKEPQGAT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)
ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
AAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC
CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00047</identifier>
        <name>ig</name>
      </pfam>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>early endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-coated endocytic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor signaling protein activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interferon-gamma-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phagocytosis, engulfment</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="10">
      <id>BE0002098</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>17704420</pubmed-id>
            <citation>Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P12318" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
    <general-function/>
    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.</specific-function>
    <gene-name>FCGR2A</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>218-240</transmembrane-regions>
    <signal-regions>1-33</signal-regions>
    <theoretical-pi>6.78</theoretical-pi>
    <molecular-weight>35000.42</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3616</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M31932</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182474</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P12318</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-a</synonym>
      <synonym>Fc-gamma-RIIa</synonym>
      <synonym>FCG2</synonym>
      <synonym>FCGR2A1</synonym>
      <synonym>FcRII-a</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-a</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a
MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS
HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
KNIYLTLPPNDHVNSNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)
ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
AAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="11">
      <id>BE0002099</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P31994" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.</specific-function>
    <gene-name>FCGR2B</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>218-240</transmembrane-regions>
    <signal-regions>1-42</signal-regions>
    <theoretical-pi>6.12</theoretical-pi>
    <molecular-weight>34043.355</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3618</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U87560</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>4099445</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31994</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-b</synonym>
      <synonym>Fc-gamma-RIIb</synonym>
      <synonym>FCG2</synonym>
      <synonym>FcRII-b</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-b</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
LEEPDDQNRI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG
CTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC
ATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC
AAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC
GACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG
TTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC
AAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC
TCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC
TACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG
ATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA
GTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG
GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
CTGGAAGAGCCTGATGACCAGAACCGTATTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="12">
      <id>BE0002100</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P31995" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
    <general-function>Transmembrane signaling receptor activity</general-function>
    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.</specific-function>
    <gene-name>FCGR2C</gene-name>
    <locus>1q23.3</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions>224-246</transmembrane-regions>
    <signal-regions>1-42</signal-regions>
    <theoretical-pi>6.9</theoretical-pi>
    <molecular-weight>35577.96</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:15626</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2C</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X17652</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>32074</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31995</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2C_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-c</synonym>
      <synonym>Fc-gamma-RIIc</synonym>
      <synonym>FCG2</synonym>
      <synonym>FcRII-c</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-c</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
GTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
TCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
GCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC
AGTAATAACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="8">
      <id>BE0001032</id>
      <name>Multidrug resistance protein 1</name>
      <organism>Human</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>12814962</pubmed-id>
            <citation>Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R: Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.</citation>
          </article>
          <article>
            <pubmed-id>11480267</pubmed-id>
            <citation>Tepper SJ: Safety and rational use of the triptans. Med Clin North Am. 2001 Jul;85(4):959-70.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08183" source="Swiss-Prot">
    <name>Multidrug resistance protein 1</name>
    <general-function>Xenobiotic-transporting atpase activity</general-function>
    <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</specific-function>
    <gene-name>ABCB1</gene-name>
    <locus>7q21.1</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.44</theoretical-pi>
    <molecular-weight>141477.255</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:40</identifier>
      </external-identifier>
<external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ABCB1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M14758</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>307180</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08183</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>MDR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.6.3.44</synonym>
      <synonym>ATP-binding cassette sub-family B member 1</synonym>
      <synonym>MDR1</synonym>
      <synonym>P-glycoprotein 1</synonym>
      <synonym>PGY1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00005</identifier>
        <name>ABC_tran</name>
      </pfam>
      <pfam>
        <identifier>PF00664</identifier>
        <name>ABC_membrane</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transporter activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>xenobiotic-transporting ATPase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATPase activity, coupled to transmembrane movement of substances</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G2/M transition of mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>stem cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </transporter>
  </transporters>
</drug>
<drug type="biotech" created="2005-06-13" updated="2018-07-03">
  <drugbank-id primary="true">DB00003</drugbank-id>
  <drugbank-id>BTD00001</drugbank-id>
  <drugbank-id>BIOD00001</drugbank-id>
  <name>Dornase alfa</name>
  <description>Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.</description>
  <cas-number>143831-71-4</cas-number>
  <unii>953A26OA1Y</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>8792953</pubmed-id>
        <citation>Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61.</citation>
      </article>
      <article>
        <pubmed-id>20238314</pubmed-id>
        <citation>Jones AP, Wallis C: Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD001127. doi: 10.1002/14651858.CD001127.pub2.</citation>
      </article>
      <article>
        <pubmed-id>19255515</pubmed-id>
        <citation>Riethmueller J, Kumpf M, Borth-Bruhns T, Brehm W, Wiskirchen J, Sieverding L, Ankele C, Hofbeck M, Baden W: Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases. Cell Physiol Biochem. 2009;23(1-3):205-10. doi: 10.1159/000204109. Epub 2009 Feb  18.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>Used as adjunct therapy in the treatment of cystic fibrosis. </indication>
  <pharmacodynamics>Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes the DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals. </pharmacodynamics>
  <mechanism-of-action>Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.</mechanism-of-action>
  <toxicity>Adverse reactions occur at a frequency of &lt; 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration (hoarseness), pharyngitis, dyspnea, laryngitis, rhinitis, decreased lung function, rash, urticaria, and conjunctivitis. There is no evidence of carcinogenic or mutagenic properties. The safety of dornase alfa has not been studied in pregnant women, nursing women and children under the age of 5 years old. </toxicity>
  <metabolism>While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids. </metabolism>
  <absorption>Studies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (less than 15% for rats and less than 2% for monkeys). The results were also witnessed in patients. Dornase alfa is also associated with very low accumulation with no serum concentration greater than 10ng/mL observed no matter the dose administered. Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. Concentrations in sputum decline rapidly after inhalation.</volume-of-distribution>
  <clearance>Studies in rats indicate that, following aerosol administration, the disappearance half-life of dornase alfa from the lungs is 11 hours. In humans, sputum DNase levels declined below half of those detected immediately post-administration within 2 hours but effects on sputum rheology persisted beyond 12 hours.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Deoxyribonuclease (human clone 18-1 protein moiety)</synonym>
    <synonym language="" coder="">Dornase alfa, recombinant</synonym>
    <synonym language="" coder="">Dornase alpha</synonym>
    <synonym language="" coder="">Recombinant deoxyribonuclease (DNAse)</synonym>
  </synonyms>
  <products>
    <product>
      <name>Pulmozyme</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50242-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA103532</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pulmozyme 1mg/ml</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02046733</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Viscozyme</name>
      <company>Roche (Chile)</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Pulmozyme 1mg/ml</name>
      <ingredients>Dornase alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pulmozyme</name>
      <ingredients>Dornase alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Catalent Pharma Solutions</name>
      <url>http://www.catalent.com</url>
    </packager>
    <packager>
      <name>F Hoffmann-La Roche Ltd.</name>
      <url>http://www.roche.com</url>
    </packager>
    <packager>
      <name>Genentech Inc.</name>
      <url>http://www.gene.com</url>
    </packager>
    <packager>
      <name>Meda AB</name>
      <url>http://www.meda.se</url>
    </packager>
    <packager>
      <name>Medpointe Pharmaceuticals</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Genentech, Inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Lufyllin 200 mg tablet</description>
      <cost currency="USD">3.21</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lufyllin-gg tablet</description>
      <cost currency="USD">3.84</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lufyllin-GG 200-200 mg tablet</description>
      <cost currency="USD">3.99</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lufyllin-400 tablet</description>
      <cost currency="USD">4.62</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lufyllin 400 mg tablet</description>
      <cost currency="USD">4.81</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pulmozyme 1 mg/ml ampul</description>
      <cost currency="USD">37.05</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Pulmozyme 1 mg/ml Solution 2.5ml Plastic Container</description>
      <cost currency="USD">77.06</cost>
      <unit>plastic</unit>
    </price>
    <price>
      <description>Lufyllin-GG 100-100 mg/15ml Elixir</description>
      <cost currency="USD">0.6</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Cough and Cold Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Deoxyribonucleases</category>
      <mesh-id>D003851</mesh-id>
    </category>
    <category>
      <category>Endodeoxyribonucleases</category>
      <mesh-id>D004706</mesh-id>
    </category>
    <category>
      <category>Endonucleases</category>
      <mesh-id>D004720</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Esterases</category>
      <mesh-id>D004950</mesh-id>
    </category>
    <category>
      <category>Expectorants</category>
      <mesh-id>D005100</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Recombinant Human Deoxyribonuclease 1</category>
      <mesh-id/>
    </category>
    <category>
      <category>Respiratory System</category>
      <mesh-id>D012137</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Respiratory (inhalation)</route>
      <strength>1 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Respiratory (inhalation)</route>
      <strength>1 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="R05CB13">
      <level code="R05CB">Mucolytics</level>
      <level code="R05C">EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS</level>
      <level code="R05">COUGH AND COLD PREPARATIONS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>44:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00003.pdf?1410715221</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00003.pdf?1410714694</msds>
  <patents>
    <patent>
      <number>2184581</number>
      <country>Canada</country>
      <approved>2005-02-22</approved>
      <expires>2015-02-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2137237</number>
      <country>Canada</country>
      <approved>2004-10-26</approved>
      <expires>2013-05-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;Dornase alfa sequence
LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP
DTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFS
RFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQ
WSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYG
LSDQLAQAISDHYPVEVMLK</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>67 °C</value>
      <source>Chan, H.K. et al., Pharm Res. 13:756-761 (1996)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.083</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>4.58</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>29253.9</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1321H1999N339O396S9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>650</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507792</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M55983</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA10318</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P24855</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000981</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Dornase_alfa</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201431</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/pulmozyme.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/dornase-alfa.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0004796</id>
      <name>DNA</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>8792953</pubmed-id>
            <citation>Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2018-07-02">
  <drugbank-id primary="true">DB00010</drugbank-id>
  <drugbank-id>BTD00033</drugbank-id>
  <drugbank-id>BIOD00033</drugbank-id>
  <name>Sermorelin</name>
  <description>Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues</description>
  <cas-number>86168-78-7</cas-number>
  <unii>89243S03TE</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of dwarfism, prevention of HIV-induced weight loss</indication>
  <pharmacodynamics>Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure. Geref increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Geref is similar to the full-length native hormone (44 residues) in its ability to stimulate GH secretion in humans.</pharmacodynamics>
  <mechanism-of-action>Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>11-12 min</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001439</drugbank-id>
      <name>Sermorelin acetate</name>
      <unii>00IBG87IQW</unii>
      <cas-number>114466-38-5</cas-number>
      <inchikey/>
    </salt>
  </salts>
  <synonyms/>
  <products/>
  <international-brands>
    <international-brand>
      <name>Geref</name>
      <company>Serono Pharma</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers>
    <packager>
      <name>Chengdu Shengnuo Bio Pharmaceutical Co. Ltd.</name>
      <url/>
    </packager>
    <packager>
      <name>Letco Medical Inc.</name>
      <url>http://www.letcomedical.com</url>
    </packager>
    <packager>
      <name>Live Well Drugstore LLC</name>
      <url>http://www.livewelldrugstore.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Emd serono inc</manufacturer>
  </manufacturers>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anterior Pituitary Lobe Hormones and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Diagnostic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Growth Hormone-Releasing Hormone</category>
      <mesh-id>D013007</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hypothalamic Hormones</category>
      <mesh-id>D007028</mesh-id>
    </category>
    <category>
      <category>Nerve Tissue Proteins</category>
      <mesh-id>D009419</mesh-id>
    </category>
    <category>
      <category>Neuropeptides</category>
      <mesh-id>D009479</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pituitary and Hypothalamic Hormones and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pituitary Hormone-Releasing Hormones</category>
      <mesh-id>D010906</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Somatropin and Somatropin Agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tests for Pituitary Function</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes>
    <atc-code code="V04CD03">
      <level code="V04CD">Tests for pituitary function</level>
      <level code="V04C">OTHER DIAGNOSTIC AGENTS</level>
      <level code="V04">DIAGNOSTIC AGENTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
    <atc-code code="H01AC04">
      <level code="H01AC">Somatropin and somatropin agonists</level>
      <level code="H01A">ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</level>
      <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;DB00010 sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSRQ</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.330</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>9.99</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>3357.882</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C149H246N44O42S</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507399</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C08192</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749110</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001055</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Sermorelin</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/sermorelin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/sermorelin-acetate.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000625</id>
      <name>Growth hormone-releasing hormone receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>14499707</pubmed-id>
            <citation>Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q02643" source="Swiss-Prot">
    <name>Growth hormone-releasing hormone receptor</name>
    <general-function>Peptide hormone binding</general-function>
    <specific-function>Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion.</specific-function>
    <gene-name>GHRHR</gene-name>
    <locus>7p14</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>133-152
163-181
205-227
241-262
281-304
330-348
362-381</transmembrane-regions>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.73</theoretical-pi>
    <molecular-weight>47401.53</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:4266</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>GHRHR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L01406</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>183173</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>247</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q02643</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>GHRHR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>GHRH receptor</synonym>
      <synonym>GRF receptor</synonym>
      <synonym>GRFR</synonym>
      <synonym>Growth hormone-releasing factor receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016157|Growth hormone-releasing hormone receptor
MDRRMWGAHVFCVLSPLPTVLGHMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWD
GLLCWPTAGSGEWVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLA
EEESYFSTVKIIYTVGHSISIVALFVAITILVALRRLHCPRNYVHTQLFTTFILKAGAVF
LKDAALFHSDDTDHCSFSTVLCKVSVAASHFATMTNFSWLLAEAVYLNCLLASTSPSSRR
AFWWLVLAGWGLPVLFTGTWVSCKLAFEDIACWDLDDTSPYWWIIKGPIVLSVGVNFGLF
LNIIRILVRKLEPAQGSLHTQSQYWRLSKSTLFLIPLFGIHYIIFNFLPDNAGLGIRLPL
ELGLGSFQGFIVAILYCFLNQEVRTEISRKWHGHDPELLPAWRTRAKWTTPSRSAAKVLT
SMC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016158|Growth hormone-releasing hormone receptor (GHRHR)
ATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTA
TTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCC
TGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGAT
GGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGAT
TTCTTCTCTCACTTCAGCTCAGAGTCAGGGGCTGTGAAACGGGATTGTACTATCACTGGC
TGGTCTGAGCCCTTTCCACCTTACCCTGTGGCCTGCCCTGTGCCTCTGGAGCTGCTGGCT
GAGGAGGAATCTTACTTCTCCACAGTGAAGATTATCTACACCGTGGGCCATAGCATCTCT
ATTGTAGCCCTCTTCGTGGCCATCACCATCCTGGTTGCTCTCAGGAGGCTCCACTGCCCC
CGGAACTACGTCCACACCCAGCTGTTCACCACTTTTATCCTCAAGGCGGGAGCTGTGTTC
CTGAAGGATGCTGCCCTTTTCCACAGCGACGACACTGACCACTGCAGCTTCTCCACTGTT
CTATGCAAGGTCTCTGTGGCCGCCTCCCATTTCGCCACCATGACCAACTTCAGCTGGCTG
TTGGCAGAAGCCGTCTACCTGAACTGCCTCCTGGCCTCCACCTCCCCCAGCTCAAGGAGA
GCCTTCTGGTGGCTGGTTCTCGCTGGCTGGGGGCTGCCCGTGCTCTTCACTGGCACGTGG
GTGAGCTGCAAACTGGCCTTCGAGGACATCGCGTGCTGGGACCTGGACGACACCTCCCCC
TACTGGTGGATCATCAAAGGGCCCATTGTCCTCTCGGTCGGGGTGAACTTTGGGCTTTTT
CTCAATATTATCCGCATCCTGGTGAGGAAACTGGAGCCAGCTCAGGGCAGCCTCCATACC
CAGTCTCAGTATTGGCGTCTCTCCAAGTCGACACTTTTCCTGATCCCACTCTTTGGAATT
CACTACATCATCTTCAACTTCCTGCCAGACAATGCTGGCCTGGGCATCCGCCTCCCCCTG
GAGCTGGGACTGGGTTCCTTCCAGGGCTTCATTGTTGCCATCCTCTACTGCTTCCTCAAC
CAAGAGGTGAGGACTGAGATCTCACGGAAGTGGCATGGCCATGACCCTGAGCTTCTGCCA
GCCTGGAGGACCCGTGCTAAGTGGACCACGCCTTCCCGCTCGGCGGCAAAGGTGCTGACA
TCTATGTGCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00002</identifier>
        <name>7tm_2</name>
      </pfam>
      <pfam>
        <identifier>PF02793</identifier>
        <name>HRM</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear inner membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear outer membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear matrix</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide hormone binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth hormone-releasing hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of intracellular steroid hormone receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell maturation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hormone metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>somatotropin secreting cell development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estrogen</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of multicellular organism growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to glucocorticoid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cAMP-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to insulin stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of insulin-like growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lactation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cAMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal reproductive process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to insulin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>growth hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>determination of adult lifespan</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>water homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of growth hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2018-07-02">
  <drugbank-id primary="true">DB00011</drugbank-id>
  <drugbank-id>BTD00096</drugbank-id>
  <drugbank-id>BIOD00096</drugbank-id>
  <drugbank-id>DB00084</drugbank-id>
  <name>Interferon alfa-n1</name>
  <description>Purified, natural (n is for natural) glycosylated human interferon alpha proteins 166 residues</description>
  <cas-number>74899-72-2</cas-number>
  <unii>41697D4Z5C</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Vladimir G. Debabov, Jury D. Tsygankov, Andrei J. Chistoserdov, Evgeny D. Sverdlov, Lara S. Izotova, Sergei V. Kostrov, Viktor E. Sterkin, Vladimir P. Kuznetsov, Sergei V. Belyaev, Galina S. Monastyrskaya, Irina S. Salomatina, Grigory M. Dolganov, Sergei G. Arsenian, Sergei A. Tsarev, Jury I. Kozlov, Alexandr Y. Strongin, Vsevolod I. Ogarkov, Jury A. Ovchinnikov, "Method for producing human leukocyte interferon alpha-2." U.S. Patent US4680260, issued January, 1982.</synthesis-reference>
  <indication>For treatment of venereal or genital warts caused by the Human Papiloma Virus</indication>
  <pharmacodynamics>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</pharmacodynamics>
  <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>1.2 hours (mammalian reticulocytes, in vitro); &amp;gt;20 hours (yeast, in vivo); &amp;gt;10 hours (Escherichia coli, in vivo).</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Interferon alpha-2</synonym>
    <synonym language="" coder="">Interferon alpha-A</synonym>
    <synonym language="" coder="">Interferon alpha-n1 (Ins)</synonym>
    <synonym language="" coder="">LeIF A</synonym>
  </synonyms>
  <products>
    <product>
      <name>Wellferon Inj 10 000 000unit/ml</name>
      <labeller>The Wellcome Foundation Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959069</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-01</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>10000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Wellferon Inj 3000000unit/ml</name>
      <labeller>The Wellcome Foundation Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959077</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-01</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>3000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Wellferon</name>
      <company>GlaxoSmithKline</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Wellferon Inj 10 000 000unit/ml</name>
      <ingredients>Interferon alfa-n1</ingredients>
    </mixture>
    <mixture>
      <name>Wellferon Inj 3000000unit/ml</name>
      <ingredients>Interferon alfa-n1</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiviral Agents</category>
      <mesh-id>D000998</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interferon Type I</category>
      <mesh-id>D007370</mesh-id>
    </category>
    <category>
      <category>Interferons</category>
      <mesh-id>D007372</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>10000000 unit</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>3000000 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AB06">
      <level code="L03AB">Interferons</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions>
    <food-interaction>Avoid alcohol.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The metabolism of Dyphylline can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Zidovudine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00011 sequence
CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C</value>
      <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.336</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.99</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>19241.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C860H1353N227O255S9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7651</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506227</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00207</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164746538</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01563</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001280</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108509</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000385</id>
      <name>Interferon alpha/beta receptor 2</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>10822464</pubmed-id>
            <citation>Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P48551" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 2</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.</specific-function>
    <gene-name>IFNAR2</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>244-264</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>4.11</theoretical-pi>
    <molecular-weight>57758.24</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5433</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L42243</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>995300</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P48551</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IFN-R-2</synonym>
      <synonym>IFNABR</synonym>
      <synonym>IFNARB</synonym>
      <synonym>Interferon alpha binding protein</synonym>
      <synonym>Type I interferon receptor 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000767|Interferon alpha/beta receptor 2
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)
ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
AGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA
CTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG
GATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to interferon-alpha</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000661</id>
      <name>Interferon alpha/beta receptor 1</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>10822464</pubmed-id>
            <citation>Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P17181" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 1</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.</specific-function>
    <gene-name>IFNAR1</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>437-457</transmembrane-regions>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>5.56</theoretical-pi>
    <molecular-weight>63524.81</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5432</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03171</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>306914</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1723</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P17181</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CRF2-1</synonym>
      <synonym>Cytokine receptor class-II member 1</synonym>
      <synonym>Cytokine receptor family 2 member 1</synonym>
      <synonym>IFN-R-1</synonym>
      <synonym>IFNAR</synonym>
      <synonym>Type I interferon receptor 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001318|Interferon alpha/beta receptor 1
MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
EDESESKTSEELQQDFV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)
ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG
TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
TTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-1 beta secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-gamma production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>T cell activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
</drugbank>